Procter & Gamble to Acquire Thorne for $3.8 Billion to Expand Health and Wellness Portfolio
Procter & Gamble is acquiring the supplement brand Thorne for $3.8 billion to strengthen its health and wellness division. Shailesh Jejurikar, CEO of Procter & Gamble, stated that the acquisition aims to grow the company's healthcare portfolio, which already includes brands like Metamucil and Vicks. The deal, set to be announced officially on Tuesday, will integrate Thorne's science-driven wellness solutions into P&G's broader healthcare segment. Paul Gama, CEO of Health Care at Procter & Gamble, noted that Thorne has built a highly trusted brand at the forefront of personalized health. The acquisition follows a period of growth for Thorne, which saw annual revenue surpass $500 million in 2025. The move reflects a broader trend of consumer interest in self-care and prevention. P&G aims to leverage Thorne's scientific rigor and practitioner credibility to reach more consumers, particularly those under the age of 40. The transaction is expected to close later in the calendar year 2026, subject to regulatory approvals.